Survodutide US FDA Breakthrough Therapy phase 3 trials MASH Survodutide US FDA Breakthrough Therapy phase 3 trials MASH Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
